The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Open accessAbstract
1. Preamble 4361 2. Introduction 4363 3. Estimation of total cardiovascular risk and implications for dyslipidaemia management 4363 4. New low-density lipoprotein cholesterol-lowering therapies 4367 5. Combination of lipid-lowering therapies during index hospitalization for acute coronary syndromes 4369 6. Lipoprotein(a) 4370 7. Hypertriglyceridaemia 4371 8. Primary prevention in people with human immunodeficiency virus infection 4372 9. Patients with cancer at high or very high chemotherapy-related cardiovascular toxicity risk 4373 10. Dietary supplements 4373 11. Evidence tables 4374 12. Data availability statement 4374 13. Author information 4374 14. Appendix 4374 15. References 4375 Recommendation Table 1 — Recommendations for cardiovascular risk estimation in persons without known cardiovascular disease (see also Supplementary data online, Evidence Table 1) 4367 Recommendation Table 2 — Recommendations for pharmacological low-density lipoprotein cholesterol lowering (see also Supplementary data online, Evidence Table 2) 4369 Recommendation Table 3 — Recommendations for lipid-lowering therapy in patients with acute coronary syndromes (see also Supplementary data online, Evidence Table 3) 4370 Recommendation Table 4 — Recommendations for measurement of lipoprotein(a) (see also Supplementary data online, Evidence Table 4) 4370 Recommendation Table 5 — Recommendations for drug treatment of patients with hypertriglyceridaemia (see also Supplementary data online, Evidence Table 5) 4372 Recommendation Table 6 — Recommendations for statin therapy in primary prevention for people with human immunodeficiency virus infection (see also Supplementary data online, Evidence Table 6) 4373 Recommendation Table 7 — Recommendations for statin therapy in patients receiving cancer therapy (see also Supplementary data online, Evidence Table 7) 4373 Recommendation Table 8 — Recommendations for dietary supplements (see also Supplementary data online, Evidence Table 8) 4374 Table 1 Classes of recommendations 4362 Table 2 Levels of evidence 4362 Table 3 Cardiovascular risk categories 4364 Table 4 Intervention strategies as a function of total cardiovascular risk and untreated low-density lipoprotein cholesterol levels 4365 Figure 1 Treatment goals for low-density lipoprotein cholesterol across categories of total cardiovascular risk 4366 Figure 2 Average reduction in low-density lipoprotein cholesterol levels with different pharmacological therapies with proven cardiovascular benefits 4368 Figure 3 Association between Lp(a) levels and lifetime risk of major cardiovascular events 4371 Acute coronary syndromes Alanine aminotransferase Apolipoprotein B Apolipoprotein C-III Antiretroviral therapy Atherosclerotic cardiovascular disease Aspartate aminotransferase Aortic valve stenosis Coronary artery calcium Confidence interval Computed tomography Cardiovascular Cardiovascular disease Docosahexaenoic acid European Atherosclerosis Society European Medicines Agency Eicosapentaenoic acid European Society of Cardiology Familial chylomicronaemia syndrome US Food and Drug Administration Familial hypercholesterolaemia High-density lipoprotein cholesterol Human immunodeficiency virus Hazard ratio Low-density lipoprotein cholesterol Lipoprotein(a) Left ventricular ejection fraction Monoclonal antibody Major adverse cardiovascular event(s) Myocardial infarction Percutaneous coronary intervention Proprotein convertase subtilisin/kexin type 9 Peroxisome proliferator-activated receptor n-3 polyunsaturated fatty acid People with HIV Systematic Coronary Risk Evaluation 2 Systematic Coronary Risk Evaluation 2-Older Persons Total cholesterol Type 1 diabetes mellitus Type 2 diabetes mellitus Upper limit of normal Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approach for an individual patient with a given condition. The European Society of Cardiology (ESC) Guidelines are intended for use by health professionals but do not override their individual responsibility to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with the patient or the patient's caregiver where appropriate and/or necessary aiming at shared care decisions. It is also the health professional's responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription and to respect the ethical rules of their profession. The ESC Guidelines represent the official position of the ESC on a given topic. Guideline topics are selected for updating after annual expert review of new evidence conducted by the ESC Clinical Practice Guidelines (CPG) Committee. ESC Policies and Procedures for formulating and issuing the ESC Guidelines can be found on the ESC website (https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines). Interim
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, the guidelines highlight that variability in LDL-C lowering is observed across all treatment options, likely reflecting differences in background LLT regimens [45].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In line with this, they emphasize the importance of monitoring LDL-C response 4 to 6 weeks after initiation or intensification and making timely treatment adjustments to achieve recommended targets [45].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recent ESC/EAS 2025 Focused Update Guideline [9] emphasizes that elevated TG and TRLs contribute independently to cardiovascular risk, even in patients achieving LDL-C targets.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recent 2025 ESC/EAS Focused Update confirms this guidance, emphasizing the persistent role of statins as the cornerstone therapy for cardiovascular risk reduction in the presence of elevated TG, not only by targeting LDL-C but also by modulating TRLs and reducing the atherogenic potential of the lipid profile [9].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The recommendations position bempedoic acid alongside other established LLTs with demonstrated cardiovascular-risk reduction such as statins, ezetimibe, and PCSK9i.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“Guidelines also recommend that the choice of treatment should not only be made based on the magnitude of additional LDL-C lowering needed, but also patient preference, treatment availability, and cost [45].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“The 2025 ESC/EAS guidelines for the management of dyslipidemia provide new recommendations for bempedoic acid in both patients unable to take statins and as an adjunct to maximally tolerated statin therapy, with or without ezetimibe, including use in high- and very high-risk patients [45].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“the 2025 ESC/EAS Focused Update [9] emphasizes that consistent cardiovascular benefit has not been demonstrated in the overall population, and fibrate therapy should therefore be reserved for carefully selected patients with persistent hypertriglyceridaemia or features of atherogenic dyslipidemia despite optimal LDL-C lowering”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Overall, the joint guideline recognizes TG/TRL-mediated risk as a modifiable component of residual cardiovascular risk, addressed pragmatically through non–HDL-C/apoB targets and selective TG-lowering therapies integrated with intensive LDL-C reduction, with non-fasting testing as the default approach.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Self-citation2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
Self-citationEzetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citation2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C. J., Andreotti, F., Koskinas, K. C., Rosselló, X., Adamo, M., Ainslie, J., BANNING, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 3,521
Self-citationLyon, A. R., López‐Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J. K., Boriani, G., Cardinale, D. M., Córdoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,457
Self-citationCardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Cited by
Sorted by citations
Items 101–200 of 817
Verpalen, V. A., Aboyans, V., Dweck, M. R., Planken, R. N., Henriques, J. P. S., Bhatt, D. L., & Nurmohamed, N. S. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag314 · Cited by 3
Chiara, E., Bagni, G., Raho, A., Fagni, F., Mohammad, A. J., & Emmi, G. (2026) · Rheumatology · doi:10.1093/rheumatology/keag268 · Cited by 3
Alotaibi, R. M., Al-Salmi, R. H., Shosho, R. O., Alzahrani, Y. A., & Harbi, M. H. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15135233 · Cited by 3
Association of Lipoprotein(a) With Coronary Atherosclerosis and Cardiovascular Events
Björnson, E., Bergström, G. M. L., Brinck, J. W., Erlinge, D., Östgren, C. J., Söderberg, S., Jernberg, T., Borén, J., & Hagström, E. (2026) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2026.05.020 · Cited by 3
Peripheral artery disease: advances in medical therapy
Garagoli, F., Slipczuk, L. N., Shapiro, M. D., Bonaca, M. P., & Bhatt, D. L. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag516 · Cited by 3
Buonerba, C., Montuori, P., Esposito, E., Triassi, M., & Cerino, P. (2026) · Toxics · doi:10.3390/toxics14090824 · Cited by 3
Dyslipidemia in Pregnancy: How to Deal
Satpathy, H. K., Mohapatra, N., Das, B., Sethi, S. P., & Kumar, B. M. (2025) · Indian Journal of Cardiovascular Disease in Women · doi:10.25259/ijcdw_61_2025 · Cited by 3
Bempedoic Acid and the Uric Acid Paradox: Reflections on the Recent Meta-analysis
Bonanni, L., & Ferri, N. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07781-3 · Cited by 2
Fit but not immune from the risk: the hidden burden of dyslipidemia in elite athletes
Celeski, M., Lavisci, P., Loddo, E. B., Calandri, C., Kowalczyk, J., Ferrera, A., Crotta, S., Rizzi, M., Sposato, B., Volterrani, M., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf607 · Cited by 2
Weltler, P., Harbich, P. F., Burger, A. L., Dobner, S., Kaufmann, C. C., Geppert, A., Huber, K., & Pogran, E. (2025) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuaf137 · Cited by 2
Why do guidelines ignore the management of type 2 myocardial infarction?
White, H. D. (2025) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuaf138 · Cited by 2
Inhibition of ATP citrate lyase does not affect muscle mitochondrial activity in apoE-/- mice
Macchi, C., Fichtner, I., Mohamed, T., Franchi, E., Rizzuto, A. S., Pavanello, C., Gindlhuber, J., Nerini, S., Sirtori, C. R., Osto, E., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118726 · Cited by 2
Self-citationCrea, F. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf847 · Cited by 2
Liu, Y., Peng, P., Hung, W., Wu, P., Kao, C., Wu, P.-Y., Huang, J., Chen, S., & Kuo, C. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104465 · Cited by 2
Sanchis‐Gomar, F., & Lippi, G. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2768-2477 · Cited by 2
Zuin, M., & Bilato, C. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-04234-5 · Cited by 2
Jang, A. Y., Lee, J. H., Lee, S., Choe, H. J., Park, S. M., Jeong, I., Kim, B. J., & on behalf of the Lipoprotein(a) Task Force of the Korea Society of Lipid and Atherosclerosis (2025) · Korean Circulation Journal · doi:10.4070/kcj.2025.0388 · Cited by 2
Khan, M., Ain, Q., Šikonja, J., Kern, B. C., Batool, H., Khan, S. A., Hayat, M. Q., Khan, M. I., Grošelj, U., & Sadiq, F. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.12.010 · Cited by 2
Muszyński, P., Dudzińska, K., Święcicka, M., Grądzka-Matys, W., Kazberuk, M., Musiałowska, D., Kruszyńska, J., Kazberuk, P., Bajda, U., & Tomaszuk−Kazberuk, A. (2025) · Diseases · doi:10.3390/diseases14010008 · Cited by 2
Amyloid‐beta (1–40) peptide is associated with systemic metabolic health
Sopova, K., Delialis, D., Aivalioti, E., Georgiopoulos, G. A., Athanasopoulos, S., Zervas, G., Konstantaki, C., Sachse, M., Sigl, M., Duerschmied, D., et al. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70171 · Cited by 2
Coronary artery calcium clinical utilization: An update
Mortada, I., Odigie‐Okon, E., Motiwala, A., Allencherril, J., Qadeer, A., Gaalema, D. E., Abdulla, A., Blackwell, T. A., & Jneid, H. M. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103258 · Cited by 2
Yamashita, I., Fujisaki, T., Kiyohara, Y., Shirahama, Y., & Kenichi, T. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag036 · Cited by 2
Jang, A. Y., Lee, J. H., Lee, S.-G., Choe, H. J., Park, S. M., Jeong, I., Kim, B. J., & on behalf of the Lipoprotein(a) Task Force of the Korea Society of Lipid and Atherosclerosis (2026) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2026.15.1.2 · Cited by 2
Intraindividual variability in lipoprotein(a)
Lakkineni, L., Waite, M., David, A., Jones, B., & Cegla, J. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.01.016 · Cited by 2
Xiao, Q., Wang, M., Wang, S., Wang, L., & Ding, H. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-025-07647-0 · Cited by 2
Zamora, A., Soler, C., Ortega, E., Martín-Urda, A. I., Mora, J., Rivas, M. C. A., Sevilla, J. C., Vila, À., Ibarrexte, D., Pérez-Bernalte, R. M., et al. (2026) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2026.500893 · Cited by 2
Kountouri, A., Ikonomidis, I., Katogiannis, K., Thymis, J., Pavlidis, G., Korakas, E., Pliouta, L., Agapitou, V., Liatis, S., Petrovski, G., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261417289 · Cited by 2
Bouillet, B., Boulestreau, R., Aboyans, V., Béliard, S., Boccara, F., Cariou, B., Charrière, S., Moulin, P., Vergès, B. L., Valéro, R., et al. (2026) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2026.01.001 · Cited by 2
Self-citationKuang, Z., Kong, R., Wang, Z., Zuo, S., You, L., Wang, X., Si, X., & Liang, J. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1743355 · Cited by 2
Impact of Lipoprotein(a) on Residual Cardiovascular Risk After an Acute Coronary Syndrome
González-Aguado, N., Franco-Hita, R., Larrubia-Valle, J. I., Puyol-Ruiz, F., Mezcua, A. R., García‐Pinilla, J. M., Jiménez-Salva, M., Piserra‐López, A., Pavón, F. J., Pérez-Cabeza, A., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15051688 · Cited by 2
Katzmann, J. L., & Laufs, U. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01390-7 · Cited by 2
Self-citationAngelantonio, E. D., Piepoli, M. F., Castelvecchio, S., Barberio, C., Chiarello, C., Cerri, A., Boveri, S., Cardani, R., Ambrogi, F., Guelfi, S., et al. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag032 · Cited by 2
Tortosa-Carreres, J., Piqueras, M., Cátedra, C., Vañó-Bellver, A., Domingo, D., Claramunt-Carbonell, T., Martínez-Dolz, L., & Laiz-Marro, B. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.120943 · Cited by 2
Rallidis, L. S., Giannakopoulou, S., Kotakos, C., Armylagos, S., Rallidis, S. L., Stathopoulou, E. P., Papathanasiou, K. A., & Panagiotakos, D. B. (2026) · Coronary Artery Disease · doi:10.1097/mca.0000000000001627 · Cited by 2
Asero, C., Oliveri, C. V., Franzè, M. S., Giovanni, A. D., Filomia, R., Caccamo, G., Pitrone, C., Saitta, C., Morace, C., Morabito, N., et al. (2026) · Journal of Endocrinological Investigation · doi:10.1007/s40618-026-02848-w · Cited by 2
Rottura, M., Drago, S. F. A., Molonia, A., Gianguzzo, V. M., Sacco, F. M., Pallio, G., Irrera, N., Scoglio, R., Marino, S., Corrao, S., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1787952 · Cited by 2
Biolo, M., Lupo, M. G., Marodin, G., Portinari, C., Zambon, A., Bertocco, S., Previato, L., Simioni, P., Ferri, N., & Zambon, S. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.03.014 · Cited by 2
Self-citationHyperuricemia risk in bempedoic acid-treated hyperlipidemic patients
Su, P., Tsai, D. H., Hsieh, M. H., Vairaperumal, T., Lai, E. C.-C., & Liu, P. Y. (2026) · Communications Medicine · doi:10.1038/s43856-026-01545-2 · Cited by 2
Lindner, B., Ausserwinkler, M., Siess, C., Ammerer, K., Esposito, M., Hermann, J., Hintenberger, R., Komposch, M., Lanser, L., Radner, H., et al. (2026) · Wiener klinische Wochenschrift · doi:10.1007/s00508-026-02718-8 · Cited by 2
Crisci, M., Ilardi, F., Manzo, R., Gragnano, F., Paolillo, R., Giugliano, G., Piro, O., Cigala, E., Monteforte, I., D’Oria, V., et al. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104728 · Cited by 2
Real-World Effectiveness of Bempedoic Acid in Reducing LDL-C
Katzmann, J. L., Becker, C., Schneider, T. F., Articus, K., Keuken, G., & Laufs, U. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.102726 · Cited by 2
Self-citationNavigating hypertriglyceridemia in pregnancy: current evidence and clinical strategies
Chamerski, S., Wartecka-Zielińska, K., Pomorski, F., Karos, W., Marlęga-Linert, J., Marcinkowska, M., Stefańska, K., Grzybowska, M. E., Wydra, D. G., Gruchała, M., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1761761 · Cited by 2
Zárate-Correa, L. C., García-Peña, Á. A., Kaiser, S. E., Aguilar-Salinas, C. A., Méndez-Castillo, M., Mehta, R., Valério, C. M., Moreira, R. O., Mancillas‐Adame, L. G., Canto, J. A. C., et al. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120783 · Cited by 2
Are we underestimating the benefits of lipid-lowering therapies?
Pirillo, A., Casula, M., Olmastroni, E., Scotti, S., Corsini, A., & Catapano, A. L. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100140 · Cited by 2
Self-citationCiaula, A. D., Khalil, M., Garruti, G., & Portincasa, P. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101056 · Cited by 2
Homozygous familial hypercholesterolaemia: insights from the Global HICC Registry
Schonck, W. A. M., Mulder, J. W. C. M., Cuchel, M., Reeskamp, L. F., Alnouri, F., Iatan, I., Freiberger, T., Kayıkçıoğlu, M., Tromp, T. R., Reijman, M. D., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag357 · Cited by 2
Self-citationBork, C., Nordestgaard, B. G., Hedegaard, B. S., Vrablik, M., Evans, E., Freiberger, T., Fras, Z., Nanchen, D., Sadiq, F., Ray, K. K., et al. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120757 · Cited by 2
Self-citationCardiovascular Risk Prediction Across the Spectrum of Measured Physical Activity
Petek, B. J., Ajufo, E. C., Churchill, T. W., Guseh, J. S., Moulson, N., Bhatia, H. S., Shapiro, M. D., Ellinor, P. T., & Khurshid, S. S. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.04.024 · Cited by 2
Nicolas, J., Oliva, A., Cohen, R. M., Sartori, S., Smith, K. F., Muro, F. M. D., Vogel, B., Hooda, A., Sharma, R., Sweeny, J. M., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag254 · Cited by 2
Hypertriglyceridaemia and its multifaceted mechanisms driving atherosclerotic cardiovascular disease
Li, X., Xu, L., Li, J., Luo, Y., Shen, H., & Zhang, D. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-026-02983-6 · Cited by 2
Lipoprotein(a) and residual cardiovascular risk in statin-treated patients
Oftadeh, S.-L., Pütz, A., Jacobsen, M., Balfanz, P., Marx, N., Brandts, J., Müller‐Wieland, D., & Verket, M. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag296 · Cited by 2
Treatment of carotid stenosis: an updated review
Lima, A. V. P., Lima, M. V. P., Marques, M. T., Gagliardi, V. D. B., & Gagliardi, R. J. (2026) · Frontiers in Stroke · doi:10.3389/fstro.2026.1849877 · Cited by 2
Tsiamis, N., Toulgaridis, F., Stefanou, E., Tountas, C., Tsitsinakis, G., Ballas, E., Maurogenis, I., Kitsiou, A., & Kole, C. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.107051 · Cited by 2
Unmet Cardiovascular Risk Beyond LDL-C: A Perspective on Managing Residual Cardiovascular Risk
Kypreos, K. E., Gafencu, A. V., Andreopoulou, O., Zvintzou, E., Marinos, K., Mparnia, V., Alemi, M., Daraban, B. S., Multescu, M. G., Ghinea, M., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19071071 · Cited by 2
Development and Validation of a Simplified Martin-Hopkins LDL-C Equation Using Machine Learning
Park, J., Fan, L., Marzinke, M. A., Sokoll, L. J., Muthukumar, A., Murphy, S. A., Sabatine, M. S., Gurudu, R., Meeusen, J. W., & Martin, S. S. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2026.2314 · Cited by 2
Self-citationCardiovascular Outcomes in Response to Achieved LDL-C Levels After PCI in ACS and CCS
Kataoka, Y., Nicholls, S. J., Ray, K. K., Katasako-Yabumoto, A., Kitahara, S., Hosoda, H., Mitsui, K., Murai, K., Sawada, K., Iwai, T., et al. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.07.004 · Cited by 2
Bobrowska, B., Dziewierz, A., Domienik‐Karłowicz, J., Zasada, W., Rajtar-Salwa, R., Rulkiewicz, A., & Siudak, Z. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.07.026 · Cited by 2
Choi, R., Chun, G., Lee, S. G., & Cho, S. E. (2026) · Metabolites · doi:10.3390/metabo16080531 · Cited by 2
Benedetto, C., Khadilkar, S. S., Nappi, R. E., Genazzani, A. R., Frezet, F., Cucinella, L., Divakar, H., Anagnostis, P. G., & Panay, N. (2026) · Climacteric · doi:10.1080/13697137.2026.2691828 · Cited by 2
Aydoğan, M., Yavuz, M. L., Yalçın, E., Özer, P. K., & Emet, S. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15166400 · Cited by 2
Ternhamar, T., Johansen, M. Ø., Nordestgaard, B. G., & Afzal, S. (2026) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2026.101814 · Cited by 2
Self-citationMontalescot, G., Ferrari, É., Souteyrand, G., Bouleti, C., Rangé, G., Batias-Moreau, L., Chioccioli, M., Picchi, A., Dillinger, J., Esposito, G., et al. (2026) · JAMA · doi:10.1001/jama.2026.17302 · Cited by 2
Self-citationAdverse pregnancy outcomes and long-term cardiovascular disease risk
Pabón, M. A., Smith, G., Sharma, G. V., Catov, J. M., Lewandowski, A. J., Adam, S., Honigberg, M. C., Sharma, G. V., Brazile, T. L., Conrad, N., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01235-3 · Cited by 3
Gagaring, T., Drummond, O., & Santulli, G. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01464-6 · Cited by 2
Morosan, A.-G., Nicolescu, A., Mocan, A., & Frumuzachi, O. (2025) · Trends in Food Science & Technology · doi:10.1016/j.tifs.2025.105454 · Cited by 2
Pechetty, R., Rao, P. S., Deb, T., Shekar, C., & Deepthi, K. (2025) · Indian Journal of Cardiovascular Disease in Women · doi:10.25259/ijcdw_55_2025 · Cited by 2
Cicero, A. F. G., Borghi, C., & Fogacci, F. (2026) · Nutrients · doi:10.3390/nu18050729 · Cited by 2
Optimising lipoprotein(a) tests: we are almost there
Langlois, M. R. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2026-0269 · Cited by 2
The Expanding Oral Options for LDL Cholesterol Management
Brunham, L. R., Shapiro, M. D., & Nambi, V. (2026) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2026.03.175 · Cited by 2
Systematic literature review on the real-world effectiveness and safety of bempedoic acid
Cicero, A. F. G., Cannon, C. P., Gautam, R., Anwar, S., Ghatak, A., Sarnes, E., Powell, H. A., Chhabra, R., & Jawla, S. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.100562 · Cited by 1
“…17, 18 ], The 2025 ESC/EAS guidelines for the management of dyslipidemia provide new recommendations for bempedoic acid in both patients unable to take statins and as an adjunct to maximally tolerated statin therapy, with or without ezetimibe, including use in high-and very high-risk patients [45].”
InfluentialWu, A.-X., Wang, X.-J., Zhao, C., Hu, J.-Q., Li, J.-W., Xu, Y., Li, Y., & Liu, S. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108178 · Cited by 1
Thevathasan, T., Schulz‐Menger, J., Gröschel, J., Backer, J. F. A. D., Borger, M. A., Gevaert, S., Laufs, U., & Pöss, J. (2025) · European Heart Journal Acute Cardiovascular Care · doi:10.1093/ehjacc/zuaf126 · Cited by 1
Self-citationYang, Y. S., Kim, S. Y., Seo, H., Lee, S., & Jung, K. J. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101323 · Cited by 1
Li, R., Dong, W., Wang, W., Duan, Y., Zhang, M., Huang, T., Hua, X., & Tang, Y. (2025) · 中国科学通报：英文版 · doi:10.1016/j.scib.2025.10.005 · Cited by 1
Antibody-Based Therapeutics for Hypercholesterolemia
Tomlinson, B., & Chan, P. (2025) · Biologics · doi:10.2147/btt.s500456 · Cited by 1
Evaluation of coronary artery calcium score by age and sex: a multicenter study
Tekinhatun, M., & Durmaz, F. (2025) · The International Journal of Cardiovascular Imaging · doi:10.1007/s10554-025-03557-w · Cited by 1
Can we better prevent cardiovascular disease? 'Stayin' healthy to stay alive'
Campbell, D. J. (2025) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2025.200553 · Cited by 1
Qiao, L., Miao, J., Du, W., Liu, Y., Chen, Y., Xu, K., Wang, C., & Chen, H. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2025.1688715 · Cited by 1
Kardiovaskuläre Bildgebung mittels Kardio-CT und -MRT
Abanador-Kamper, N., Giannopoulos, A. A., Georgiadis, M., & Korosoglou, G. (2025) · Herz · doi:10.1007/s00059-025-05350-w · Cited by 1
Maligłówka, M., Sojka, A., Dec, A., Okopień, B., & Bułdak, Ł. (2025) · Endokrynologia Polska · doi:10.5603/ep.108425 · Cited by 1
Ērglis, K., Kokina, B., Jēgere, S., Mintāle, I., Jakobsons, E., Bartkevičs, V., Ērglis, M., Zuzans, R., Narbute, I., Trušinskis, K., et al. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12120478 · Cited by 1
ESC-Leitlinien-Update 2025 zur Dyslipidämie
Hohneck, A. L., & Weingärtner, O. (2025) · Herz · doi:10.1007/s00059-025-05354-6 · Cited by 1
Self-citationManaging cardiovascular risk factors in patients with Sjögren’s disease: a comprehensive approach
Giuggioli, D., Mattioli, A. V., & Pinti, M. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2603895 · Cited by 1
Jiang, S., Li, L., Miao, Y., Aa, G., Liu, H., Chen, X., Sun, H., Fang, Y., Sun, P., Zhou, X., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101391 · Cited by 1
Ding, W., Sun, L., Shi, Y., & Tian, L. (2025) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2025.200568 · Cited by 1
Miteva, K., & Mach, F. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf1009 · Cited by 1
Self-citationTroy, A. L., Anderson, T. S., Razavi, A. C., Schott, S. L., Spitz, J. A., & Blumenthal, R. S. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101410 · Cited by 1
Iwanowski, M., Pappalettere, C. C., Vime‐Jubany, J., Velescu, A., Marcos, L., Chalela, R., Zuccarino, F., Maiques, J. M., Tizón‐Marcos, H., Vaquerizo, B., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101396 · Cited by 1
Elhiny, R., O’Keeffe, L. M., Millar, S., Byrne, S., Bermingham, M., & Donovan, M. D. (2026) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2026.102286 · Cited by 1
Chiusolo, S., Masini, G., Zywicki, V., Bort, I. R., Malloggi, L., Gargani, L., Palagi, C., & Caterina, R. D. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.134140 · Cited by 1
Razavi, A. C., Sokolsky, M., Belanger, M., Blazoski, C. M., Spitz, J. A., Sperling, L. S., Blumenthal, R. S., & Whelton, S. P. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101417 · Cited by 1
Iwanowski, M., Ruiz, S., Vime‐Jubany, J., Zuccarino, F., Zerpa, D. Á. P., Jimenez-Mayorga, L., Rodríguez, S., Rodriguez, N., Cabero, P., Ivern, C., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101416 · Cited by 1
Paolucci, M., Urbinati, G., Gentile, M., Forlivesi, S., Arnone, G., Migliaccio, L., Viola, M. M., Galluzzo, S., Fanciulli, C., Sebastiani, M., et al. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.01.015 · Cited by 1
Mandaglio‐Collados, D., Ramos‐Bratos, M. P., Rivera‐Caravaca, J. M., Soler‐Espejo, E., Roldán, V., Lip, G. Y. H., López‐Gálvez, R., & Marín, F. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag061 · Cited by 1
Self-citationLDL-C lowering in patients treated with bempedoic acid in a real-world cohort
Nelson, J., Bloedon, L. T., Lewandowski, D., Vaduganathan, M., Ajose, M., Bonafede, M., & Sarnes, E. (2026) · Atherosclerosis Plus · doi:10.1016/j.athplu.2026.01.007 · Cited by 1
Laysandro, R., Harijanto, E. A., & Sie, N. A. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1737431 · Cited by 1
Residual coronary atherosclerotic risk and low LDL-cholesterol in chronic coronary syndromes
Neglia, D., Pane, K., Occhipinti, M., Gori, C. D., Rocchiccioli, S., Ragusa, R., Cavaliere, C., Zanfardino, M., Prontera, C., Botto, N., et al. (2026) · European Heart Journal - Imaging Methods and Practice · doi:10.1093/ehjimp/qyag021 · Cited by 1
Kang, S., Kwon, S. U., Lee, J.-Y., Seo, S. M., Nam, C., Park, G.-M., Hong, Y. J., Lee, W. Y., Jang, J. E., & Chae, I. H. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05594-2 · Cited by 1
Addeo, L., Guarini, P., Tedeschi, C., Rapacciuolo, A., Severino, S., Michele, M. D., Sidiropulos, M., Silvestre, M., Liguori, C., Cocchiara, L., et al. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13020088 · Cited by 1
The 2025 ESC/EAS Dyslipidaemia Focused Update: Clinical Interpretation and Practical Implications
Bonanni, L., Cutolo, A., & Ferri, N. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07855-w · Cited by 1
Metadata
- Authors
- Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., Tokgözoğlu, L., Badimon, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G. G., Delgado, V., Fabin, N., Ference, B. A., Graham, I. M., Landmesser, U., Laufs, U., Mihaylova, B., Nordestgaard, B. G., Richter, D. J., Sabatine, M. S., ESC/EAS Scientific Document Group, Mueller, C. E., Drexel, H., Abreu, A., Adamo, M., Aktaa, S., Asselbergs, F. W., Baldini, A., Boriani, G., Brida, M., Brodmann, M., Cenko, E., Dagres, N., Dopheide, J., Ebenbichler, C., Gandjbakhch, E., Gorog, D. A., Gouni-Berthold, I., Guasti, L., Heidecker, B., Ibanez, B., James, S., Juni, P., Kałużna-Oleksy, M., Krychtiuk, K. A., Lip, G. Y. H., Lorusso, R., Mahfoud, F., Metra, M., Moelgaard, I., Morais, J., Neubeck, L., Nissen, S. E., Osto, E., Parhofer, K. G., De Isla, L. P., Pesce, M., Petrulioniene, Z., Prescott, E., Rietzschel, E., Rocca, B., Rodriguez Palomares, J. F., Rossello, X., Sannino, A., Semb, A. G., Siller-Matula, J. M., Socrates, T., Tanner, F. C., Wojta, J., Zambon, A., Zeppenfeld, K., Laredj, N., Hayrapetyan, H., Speidl, W. S., Samadov, F., van de Borne, P., Kusljugic, Z., Postadzhiyan, A., Heracleous, H., Ostadal, P., Henriksen, F. L., Mohamed, M. S., Viigimaa, M., Juonala, M., Boccara, F., Chukhrukidze, A., Weingärtner, O., Marketou, M., Kiss, R. G., Sigurdsson, A. F., Maher, V., Henkin, Y., Nodari, S., Bekbossynova, M., Ibrahimi, P., Mirrakhimov, E., Jegere, S., Arnaout, S., Bheleel, O., Plisiene, J., Visser, L., Abela, M., Ivanov, V., Boskovic, A., Mbarek, N., Leening, M. J. G., Bosevski, M., Vesterbekkmo, E. K., Kubica, J., Ferreira, J., Pop, D., Stefanelli, U. M., Giga, V., Pella, D., Fras, Z., Fernandez-Olmo, R., Nilsson, L., Sudano, I., Marjeh, M. Y. B., Triki, F., Degertekin, M. M., Mitchenko, O., Banerjee, A., & Shek, A.
- Affiliations
- (Switzerland)
- (Netherlands)
- (Türkiye)
- (Spain)
- (United Kingdom)
- (Denmark)
- (Austria)
- (Italy)
- (Belgium)
- (Ireland)
- (Germany)
- (Greece)
- (United States of America)
- (Portugal)
- (Croatia)
- (France)
- (Sweden)
- (Poland)
- (Austria/Switzerland)
- (Italy/Saudi Arabia)
- (Lithuania)
- (Norway)
- Corresponding author
- Mach, François
- Koskinas, Konstantinos C
- ORCID
- Mach, François
- Koskinas, Konstantinos C
- Roeters van Lennep, Jeanine E
- Tokgözoğlu, Lale
- Badimon, Lina
- Baigent, Colin
- Benn, Marianne
- Binder, Christoph J
- Catapano, Alberico L
- De Backer, Guy G
- Delgado, Victoria
- Fabin, Natalia
- Graham, Ian M
- Landmesser, Ulf
- Laufs, Ulrich
- Mihaylova, Borislava
- Nordestgaard, Børge Grønne
- Richter, Dimitrios J
- Sabatine, Marc S
- Mueller, Christian Eugen
- Drexel, Heinz
- Abreu, Ana
- Adamo, Marianna
- Aktaa, Suleman
- Asselbergs, Folkert W
- Boriani, Giuseppe
- Brida, Margarita
- Brodmann, Marianne
- Cenko, Edina
- Dagres, Nikolaos
- Dopheide, Jörn
- Ebenbichler, Christoph
- Gandjbakhch, Estelle
- Gorog, Diana A
- Guasti, Luigina
- Heidecker, Bettina
- James, Stefan
- Krychtiuk, Konstantin A
- Lip, Gregory Y H
- Lorusso, Roberto
- Mahfoud, Felix
- Metra, Marco
- Neubeck, Lis
- Nissen, Steven E
- Osto, Elena
- Parhofer, Klaus G
- Pesce, Maurizio
- Prescott, Eva
- Rietzschel, Ernst
- Rocca, Bianca
- Sannino, Anna
- Semb, Anne Grete
- Siller-Matula, Jolanta M
- Socrates, Thenral
- Tanner, Felix C
- Wojta, Johann
- Zambon, Alberto
- Zeppenfeld, Katja
- Hayrapetyan, Hamlet
- Speidl, Walter Stefan
- Samadov, Fuad
- van de Borne, Philippe
- Postadzhiyan, Arman
- Henriksen, Finn Lund
- Juonala, Markus
- Boccara, Franck
- Chukhrukidze, Archil
- Weingärtner, Oliver
- Marketou, Maria
- Nodari, Savina
- Bekbossynova, Makhabbat
- Mirrakhimov, Erkin
- Bheleel, Osama
- Abela, Mark
- Ivanov, Victoria
- Leening, Maarten J G
- Bosevski, Marijan
- Vesterbekkmo, Elisabeth K
- Kubica, Jacek
- Ferreira, Jorge
- Pop, Dana
- Giga, Vojislav
- Pella, Daniel
- Sudano, Isabella
- Triki, Faten
- Mitchenko, Olena
- Banerjee, Amitava
- Shek, Aleksandr
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2025-08-29
- Volume
- 46
- Issue
- 42
- Pages
- 4359-4378
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W4413804012
- Cited by
- 688
- References
- 136
- Citations by year
- 2026: 601 · 2025: 87
- FWCI
- 649.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Keywords
- dyslipidemia, dyslipidemia management, cardiovascular risk prediction, LDL-C lowering therapy, acute coronary syndrome, lipoprotein(a), hypertriglyceridemia, HIV infection, cancer patients, statins, dietary supplements, treatment goals, cardiovascular risk reduction, cardiovascular mortality, cardiovascular hospitalization, cardiovascular disease prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
